FDA Drug recall D-0649-2017
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd
- FDA Drug
- Class III
- terminated
- Published 2017-04-12
On 2017-04-12 the FDA classified a Class III recall of RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd by Dr Reddy S Laboratories, citing cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0649-2017 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2017-03-06 |
| Published | 2017-04-12 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Dr Reddy S Laboratories |
| Distribution | US |
Product
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60
Reason
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Identifiers
| ndc | 55111-352-30 |
|---|---|
| ndc | 55111-352-60 |
| ndc | 55111-352-01 |
| ndc | 55111-352-05 |
| ndc | 55111-353-30 |
| ndc | 55111-353-60 |
| ndc | 55111-353-01 |
| ndc | 55111-353-05 |
| ndc | 55111-354-30 |
| ndc | 55111-354-60 |
| ndc | 55111-354-01 |
| ndc | 55111-354-05 |
| ndc | 55111-355-30 |
| ndc | 55111-355-60 |
| ndc | 55111-355-01 |
| ndc | 55111-355-05 |
| code_info | Lot #C607323, Exp 10/18 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0649-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.